GSK News Today - Search News

GSK announces EMA accepted for review MAA for depemokimab

EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).

Business Insider · 1d

GSK announces EMA accepted for review the MAA for depemokimab

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use

Seeking Alpha · 1d

GSK says asthma and nasal polyps therapy under EU review

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here.

Hosted on MSN · 1d

GSK's depemokimab gets EMA nod for asthma and nasal polyps

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a significant milestone as the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application for depemokimab,

Pharmabiz · 8h

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS

GSK Pharma put volume heavy and directionally bearish

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...

pharmaphorum2d

GSK backs £50m Oxford University cancer vaccine programme

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

GSK rises Thursday, outperforms market

Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...

Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

FierceBiotech2d

GSK offers up to £50M to conduct cancer vaccine research with the University of Oxford

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

7don MSN

Anywhere under £45.27, GSK’s share price looks cheap to me

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

GSK rises Tuesday, outperforms market

Shares of GSK PLC GSK inched up 0.33% to £13.59 Tuesday, on what proved to be an all-around positive trading session for the ...

2don MSN

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results